Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
400

Inclusion Criterias

Smoke more than 10 cigarettes/day
Able to read and understand English
Age 18 years or older
...
Smoke more than 10 cigarettes/day
Able to read and understand English
Age 18 years or older
Patient enrolled in the HIV clinic with HIV or AIDS diagnosis

Exclusion Criterias

Are already participating in other smoking cessation interventions.
Are in recovery for pathological gambling (PG)
Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
...
Are already participating in other smoking cessation interventions.
Are in recovery for pathological gambling (PG)
Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)

Summary

Conditions
  • AIDS
  • HIV
  • Nicotine Dependence
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Description

All research related activities will take place at the Tolan Park Medical Building located at 3901 Chrysler Service Dr, Detroit, 48201. Participants in Phase 1 will be randomized to one of two brief interventions based on standard of care guidelines (SoC): A) brief counseling and bupropion (SoC); or...

All research related activities will take place at the Tolan Park Medical Building located at 3901 Chrysler Service Dr, Detroit, 48201. Participants in Phase 1 will be randomized to one of two brief interventions based on standard of care guidelines (SoC): A) brief counseling and bupropion (SoC); or B) SoC plus brief high-magnitude prize CM (HM-CM). At the end of Phase 1, participants will be classified as responders or non-responders on the basis of smoking reduction/abstinence. All participants will continue to receive bupropion. Non-responders will enter Phase 2a and be randomly assigned to: A) continued counseling and monitoring support to quit smoking (MS); or B) MS plus prize CM for abstinence (MS+CM). Phase 1 responders will be entered into Phase 2b and randomly assigned to: A) no additional treatment (NAT); or B) Continued monitoring and low intensity prize CM (LI-CM). The primary dependent variables will include cotinine and carbon monoxide (CO) levels, and longest duration of abstinence from cigarettes. Seven-day point prevalence will be used to assess outcome at post-treatment, 6-month and 12-month follow-up points. Participants will be paid $35 for intake and $25 for each follow-up interview, which will occur at post-phase 1, post-phase 2, and 6-months and 12-months after treatment initiation. Some assessments as well as treatment sessions will be recorded to ensure data quality.

Inclusion Criterias

Smoke more than 10 cigarettes/day
Able to read and understand English
Age 18 years or older
...
Smoke more than 10 cigarettes/day
Able to read and understand English
Age 18 years or older
Patient enrolled in the HIV clinic with HIV or AIDS diagnosis

Exclusion Criterias

Are already participating in other smoking cessation interventions.
Are in recovery for pathological gambling (PG)
Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
...
Are already participating in other smoking cessation interventions.
Are in recovery for pathological gambling (PG)
Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)

Locations

Detroit, Michigan, 48201
Detroit, Michigan, 48201

Tracking Information

NCT #
NCT01965405
Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
  • Principal Investigator: David Ledgerwood, PhD Wayne State University
  • David Ledgerwood, PhD Wayne State University